Special Issue

The Role of Lactate Isomers in Cancer

Message from the Guest Editors

Dear colleagues, L- and D-lactate both derive from the triose phosphate intermediates of glycolysis. Since the rate of glycolysis increases in tumors, both L- and D-lactate formation could be considered a hallmark of increased glucose consumption in cancer. Even if far less is known about D-lactate than L-isomer, especially in cancer, the importance of both L- and D-lactate formation, transport, and metabolic fate clearly emerges from earlier and recent discoveries. This Special Issue focuses on the study of lactate isomers, from their production to their transport and oxidation, both in normal and cancer cells, stressing the role of these compounds in cell metabolism, signaling, as well as in cell interactions within the tumor. Studies exploring the involvement of mitochondria in these processes are also welcome. We firmly believe that the present Special Issue, by bringing together all the achievements on lactate biochemistry, will represent an important overview on this complex topic and highlight the missing tiles from a mosaic that promises to indicate novel therapeutic perspectives for the cure of cancer patients. We look forward to receiving your contributions.

Guest Editors

Dr. Lidia de Bari

Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), Italian National Research Council (CNR), Bari, Italy

Dr. Miklós Péter Kalapos

Theoretical Biology Research Group, Budapest, Hungary

Deadline for manuscript submissions

closed (31 December 2022)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/118986

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)